On October 23, the FDA approved levoleucovorin for injection (Khapzory, Spectrum Pharmaceuticals, Inc.) for three indications: Rescue after high-dose methotrexate therapy in patients with osteosarcoma Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination The treatment of patients with metastatic colorectal cancer (mCRC) in combination with fluorouracil. Read the Spectrum Pharmaceuticals press release here.
